Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
Recalling Firm: Marketed health products
Reason for Recall / Hazard
New safety information - Product safety
Product Description & Identification
Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism
Affected Products
CRYSVITA (burosumab)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 77973 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/important-safety-information-crysvita-burosumab-and-risk-severe-hypercalcemia-patients |
| Issue | New safety information - Product safety |
| Title | Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism |
| Product | CRYSVITA (burosumab) |
| Archived | 0 |
| Category | Biologic or vaccine |
| Last updated | 2025-08-25 |
| Organization | Marketed health products |
Check Other Products In Your Household
Free Safety ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMarketed health products
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Marketed health products - Important Safety Information on CRYSVITA (burosumab) and the Risk of Severe Hypercalcemia in Patients with Tertiary Hyperparathyroidism Check if your household is affected: https://therecallfile.com/recalls/important-safety-information-on-crysvita-burosumab-and-the-risk-of-sev/CANADA-77973
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Support The Recall File
Help keep official recall alerts free, accessible, and fast for everyone.